July 25, 2014 12:57 PM ET

Biotechnology

Company Overview of 3SBio Inc.

Company Overview

3SBio Inc., a biotechnology company, engages in the research and development, manufacture, and marketing of bio-pharmaceutical products. Its principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombocytopenia. The company also markets Intefen, a recombinant interferon alpha-2a product to treat carcinoma and viral infectious diseases; Inleusin, a recombinant human interleukin-2 product to treat renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused b...

No. 3 A1, Road 10

Shenyang Economy & Technology Development Zone

Shenyang,  110027

China

Founded in 1993

891 Employees

Phone:

86 24 2581 1820

Fax:

86 24 2581 1821

Key Executives for 3SBio Inc.

Co-Founder
Age: 51
Co Founder and Advisor
Age: 78
Chief Financial Officer
Age: 41
Chief Technology Officer
Age: 44
Vice President and Corporate Secretary
Age: 46
Compensation as of Fiscal Year 2014.

3SBio Inc. Key Developments

Selecta Biosciences Inc Enters into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout

Selecta Biosciences Inc. announced it has entered into an exclusive license with 3SBio for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis. Pegsiticase has shown the ability to efficiently reduce plasma uric acid levels in gout patients in successful U.S. Phase 1 clinical tests. The exclusive license enables Selecta to develop pegsiticase in patients with refractory and tophaceous gout and apply its immunomodulatory Synthetic Vaccine Particle (SVP) platform to optimize the safety and efficacy profile for patients at risk of immunogenicity. SEL-212 is a novel product that combines Selecta's proprietary SVP with 3SBio's pegsiticase and is designed to be the first non-immunogenic version of uricase. Selecta will work with 3SBio to advance pegsiticase-based therapeutics as potential treatments for refractory and tophaceous gout as well as tumor lysis syndrome, with the ultimate goal of expeditiously moving toward regulatory approvals. Selecta and 3SBio have agreed to work together to achieve clinical proof of concept for SEL-212 and pegsiticase in human clinical trials in their territories; Selecta's territory includes US and all of Europe. Proof-of-concept clinical studies are expected to be initiated in 2015. Additional terms of the exclusive license granted by 3SBio to Selecta are not being disclosed.

3SBio Inc. Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 01:30 PM

3SBio Inc. Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 01:30 PM. Venue: Kempinski Hotel Suzhou, Suzhou, China. Speakers: Bo Tan, Chief Financial Officer, Principal Accounting Officer and Member of Investment Committee.

3SBio Inc. Presents at 2013 BIO Convention in China, Nov-13-2013 09:00 AM

3SBio Inc. Presents at 2013 BIO Convention in China, Nov-13-2013 09:00 AM. Venue: China National Convention Center, No.7 Tianchen East Road, Chaoyang District, Beijing 100105, China.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 3SBio Inc., please visit www.3sbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.